CRITICAL INNOVATIONS LLC — Department of Defense SBIR Phase I: CBD212-005
CRITICAL INNOVATIONS LLC — SBIR Phase I award from Department of Defense.
- Amount
- $167,500
- Agency
- Department of Defense · Office for Chemical and Biological Defense
- Program / Phase
- SBIR · Phase I
- Topic
- CBD212-005
- Solicitation
- 21.2
- NAICS
- —
- Place of performance
- CA
- Period
- 2022-02-22 → 2022-08-22
Description
The Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical (JPM CBRN Medical) seeks to develop dermal dressing technologies that provide multiple advantages over current wound dressings for treating dermal injuries caused by sulfur mustard. Critical Innovations, Battelle's Biomedical Research Center, and NDA Partners, with consultants Captain David Tanen, MD, FAAEM, FACMT (USN, Ret.) and Dr. David Greenhalgh, MD, FACS, have formed a team of medical device experts to address this important medical need. During this Phase I project, our objectives will be to further advance the innovative Succor product. This will include: 1) On-boarding program requirements, goals, and schedule; 2) Gathering existing data on the efficacy of Succor for treatment of similar dermal injuries; 3) Formalizing a regulatory plan to obtain an FDA indication for HD dermal injury; 4) Preparing a draft research plan for subsequent small-animal studies; and, 6) Maintaining all regulatory compliance requirements while preparing for upcoming regulatory and transition hurdles (TRL 6).